Literature DB >> 7695232

Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients.

E K Richfield1, K A Maguire-Zeiss, C Cox, J Gilmore, P Voorn.   

Abstract

Differential loss of neurons and terminals occurs in Huntington's disease. Neurons expressing preproenkephalin (PPE) appear to be more vulnerable than neurons expressing preprotachykinin and terminals in the lateral pallidum (containing enkephalin) are more affected than terminals in the medial pallidum (containing substance P). We used in situ hybridization histochemistry and emulsion autoradiography to quantify the number of PPE expressing neurons and the neuronal levels of PPE mRNA in striatum of individuals who died with Huntington's disease and normal controls. We found a grade-related decline in the number of PPE-labeled neurons per field in the striatum of individuals with Huntington's disease compared with controls. Three measures of the neuronal level of PPE mRNA, the mean number of silver grains per PPE neuron, the median number of grains per PPE neuron, and the percentage of PPE neurons with more than 30 grains, were all significantly reduced (41 to 80% of control) in Huntington's disease striatum. The magnitude of the reduction in levels of PPE mRNA per neuron was related to the grade of lesions. These data support the notion that decreased levels of PPE mRNA may account, in part, for the greater loss of enkephalin staining in lateral pallidal terminals compared with substance P staining in medial pallidal terminals. Decreased levels of PPE mRNA may result in clinical symptoms prior to the loss of neurons. The reduction in expression of PPE mRNA suggests that surviving striatal neurons may be affected by the expression of the Huntington's disease gene prior to their imminent cell death.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7695232     DOI: 10.1002/ana.410370309

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  23 in total

1.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

2.  Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.

Authors:  Lianwu Fu; Ya-sheng Gao; Elizabeth Sztul
Journal:  Neurobiol Dis       Date:  2005-06-16       Impact factor: 5.996

3.  Differential localization of the GluR1 and GluR2 subunits of the AMPA-type glutamate receptor among striatal neuron types in rats.

Authors:  Y P Deng; J P Xie; H B Wang; W L Lei; Q Chen; A Reiner
Journal:  J Chem Neuroanat       Date:  2007-03-04       Impact factor: 3.052

4.  Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease.

Authors:  F R Fusco; Q Chen; W J Lamoreaux; G Figueredo-Cardenas; Y Jiao; J A Coffman; D J Surmeier; M G Honig; L R Carlock; A Reiner
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

5.  Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.

Authors:  Lisa M Stanek; Sergio P Sardi; Bryan Mastis; Amy R Richards; Christopher M Treleaven; Tatyana Taksir; Kuma Misra; Seng H Cheng; Lamya S Shihabuddin
Journal:  Hum Gene Ther       Date:  2014-03-21       Impact factor: 5.695

6.  Neurons lacking huntingtin differentially colonize brain and survive in chimeric mice.

Authors:  A Reiner; N Del Mar; C A Meade; H Yang; I Dragatsis; S Zeitlin; D Goldowitz
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

Review 7.  Genetics and neuropathology of Huntington's disease.

Authors:  Anton Reiner; Ioannis Dragatsis; Paula Dietrich
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

8.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Authors:  Kristina Becanovic; Mahmoud A Pouladi; Raymond S Lim; Alexandre Kuhn; Paul Pavlidis; Ruth Luthi-Carter; Michael R Hayden; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

9.  Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.

Authors:  Cheryl L Wellington; Lisa M Ellerby; Claire-Anne Gutekunst; Danny Rogers; Simon Warby; Rona K Graham; Odell Loubser; Jeremy van Raamsdonk; Roshni Singaraja; Yu-Zhou Yang; Juliette Gafni; Dale Bredesen; Steven M Hersch; Blair R Leavitt; Sophie Roy; Donald W Nicholson; Michael R Hayden
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

Review 10.  Huntington disease models and human neuropathology: similarities and differences.

Authors:  Jean Paul G Vonsattel
Journal:  Acta Neuropathol       Date:  2007-11-03       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.